Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Oncology|April 6, 2005
High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancerJ Stemmler, W Mair, M Stauch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy useW Eiermann, M Rezai, S Kümmel, et al.
ESMO Open|July 31, 2026
Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancerC Jackisch, S-A Im, A Mattar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO studyG von Minckwitz, S Kümmel, A du Bois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2008
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trialO Gluz, U A Nitz, N Harbeck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patientsV Möbus, G von Minckwitz, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseS Loibl, A Schneeweiss, J Huober, et al.
Oncology (Williston Park, N.Y.)|February 3, 2005
Anthracycline and trastuzumab in breast cancer treatmentM Untch, I Himsl, S Kahlert, et al.
Zentralblatt Fur Gynakologie|December 26, 2001
[Preoperative chemotherapy in primary operable breast cancer with a dose-dense combination of doxorubicin and docetaxel (ADoc) - Experience of the GEPARDO-GABG study group]G von Minckwitz, G Raab, M Schütte, et al.
Pageof 10